← Back to Search

Unknown

IMB-1018972 for Hypertrophic Cardiomyopathy (IMPROVE-HCM Trial)

Phase 2
Waitlist Available
Research Sponsored by Imbria Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 14 safety follow-up
Awards & highlights

Summary

This trial is testing a new drug for people with non-obstructive HCM to see if it is safe and effective.

Eligible Conditions
  • Hypertrophic Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 14 safety follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through week 14 safety follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs
Secondary outcome measures
Oxygen

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IMB-1018972 200mgExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMB-1018972
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Imbria Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
748 Total Patients Enrolled
Paul Chamberlin, MDStudy DirectorImbria Pharmaceuticals, Inc.
6 Previous Clinical Trials
1,887 Total Patients Enrolled
Medical MonitorStudy ChairImbria Pharmaceuticals, Inc.
1,672 Previous Clinical Trials
988,401 Total Patients Enrolled
~16 spots leftby Jul 2025